Your browser is no longer supported. Please, upgrade your browser.
Olema Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.62 Insider Own9.50% Shs Outstand38.52M Perf Week-31.21%
Market Cap943.58M Forward P/E- EPS next Y-2.24 Insider Trans63.67% Shs Float34.65M Perf Month-31.08%
Income-24.00M PEG- EPS next Q-0.28 Inst Own87.70% Short Float3.29% Perf Quarter-48.53%
Sales- P/S- EPS this Y-455.80% Inst Trans0.33% Short Ratio6.62 Perf Half Y-
Book/sh8.78 P/B2.51 EPS next Y-69.70% ROA- Target Price- Perf Year-
Cash/sh7.89 P/C2.79 EPS next 5Y- ROE- 52W Range23.27 - 60.27 Perf YTD-54.24%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-63.50% Beta-
Dividend %- Quick Ratio74.60 Sales past 5Y- Gross Margin- 52W Low-5.46% ATR2.58
Employees36 Current Ratio74.60 Sales Q/Q- Oper. Margin- RSI (14)27.55 Volatility9.98% 7.74%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume1.01 Prev Close23.34
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume172.16K Price22.00
Recom1.50 SMA20-30.96% SMA50-39.11% SMA200-47.24% Volume173,048 Change-5.74%
Dec-14-20Initiated JP Morgan Overweight $52
Dec-14-20Initiated Jefferies Buy $70
Dec-14-20Initiated Cowen Outperform
Dec-14-20Initiated Canaccord Genuity Buy $60
Apr-07-21 07:30AM  
Apr-06-21 07:30AM  
Mar-17-21 04:05PM  
Mar-10-21 04:45PM  
Feb-23-21 07:00AM  
Feb-19-21 04:59AM  
Dec-31-20 03:42PM  
Dec-17-20 07:00AM  
Dec-07-20 07:39AM  
Dec-03-20 05:18PM  
Nov-23-20 04:01PM  
Nov-20-20 01:33PM  
Nov-19-20 06:39PM  
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cormorant Asset Management, LPFormer 10% OwnerNov 23Buy19.00425,0008,075,0003,270,544Nov 23 04:59 PM
Graham G. WalmsleyDirectorNov 23Buy19.001,160,00022,040,0001,160,000Nov 23 04:35 PM